T4	GGPs 401 420	monoclonal antibody
T5	Disorder 1707 1740	upper respiratory tract infection
T6	GGPs 1563 1575	tralokinumab
T7	Entity_Property 439 455	mild to moderate
T9	Subject 384 389	human
T13	Disorder 158 187	idiopathic pulmonary fibrosis
T14	GGPs 1789 1801	Tralokinumab
T17	GGPs 1584 1596	tralokinumab
T18	GGPs 1456 1468	tralokinumab
T19	Disorder 1622 1627	cough
T20	Artificial_process 1525 1534	treatment
T25	GGPs 940 952	tralokinumab
T26	Disorder 189 192	IPF
T29	Subject 680 690	population
T39	Artificial_process 1249 1258	treatment
T59	GGPs 964 976	tralokinumab
T65	Anatomical_entity 230 236	tissue
T66	Disorder 1649 1652	IPF
T74	GGPs 368 380	tralokinumab
T77	GGPs 41 53	Tralokinumab
T80	GGPs 488 500	tralokinumab
T81	Subject 757 766	subgroups
T82	Subject 1268 1277	subgroups
T83	GGPs 1289 1298	periostin
T85	Gene_expression 251 261	expression
T88	Disorder 456 459	IPF
T89	Disorder 71 100	Idiopathic Pulmonary Fibrosis
T92	Anatomical_entity 781 786	serum
T103	GGPs 787 796	periostin
E2	Artificial_process:T20 Instrument:T6 Instrument2:T17 Instrument3:T63
E5	Artificial_process:T39 Theme:T2
E11	Gene_expression:T85 Theme:T107
N11	Reference T4 UMLS:C0003250	Monoclonal Antibodies
N12	Reference T5 UMLS:C0041912	Upper Respiratory Infections
N16	Reference T6 UMLS:C3658667	tralokinumab
N17	Reference T7 UMLS:C1299392	Mild to moderate
N22	Reference T9 UMLS:C0086418	Homo sapiens
N31	Reference T13 UMLS:C1800706	Idiopathic Pulmonary Fibrosis
N36	Reference T14 UMLS:C3658667	tralokinumab
N44	Reference T17 UMLS:C3658667	tralokinumab
N47	Reference T18 UMLS:C3658667	tralokinumab
N52	Reference T19 UMLS:C0010200	Coughing
N65	Reference E2 UMLS:C0087111	Therapeutic procedure
N84	Reference T25 UMLS:C3658667	tralokinumab
N86	Reference T26 UMLS:C1800706	Idiopathic Pulmonary Fibrosis
N100	Reference T29 UMLS:C1257890	Population Group
N138	Reference E5 UMLS:C0087111	Therapeutic procedure
N221	Reference T59 UMLS:C3658667	tralokinumab
N243	Reference T66 UMLS:C1800706	Idiopathic Pulmonary Fibrosis
N265	Reference T74 UMLS:C3658667	tralokinumab
N275	Reference T77 UMLS:C3658667	tralokinumab
N283	Reference T80 UMLS:C3658667	tralokinumab
N293	Reference T83 UMLS:C0219433	POSTN protein, human
N308	Reference T88 UMLS:C1800706	Idiopathic Pulmonary Fibrosis
N310	Reference T89 UMLS:C1800706	Idiopathic Pulmonary Fibrosis
N327	Reference T92 UMLS:C0229671	Serum
N361	Reference T103 UMLS:C0219433	POSTN protein, human
T106	Disorder 439 459	mild to moderate IPF
N1	Reference T106 UMLS:C1800706	Idiopathic Pulmonary Fibrosis
T37	Pharmacological_substance 521 528	placebo
T43	Pharmacological_substance 1500 1507	placebo
T63	Pharmacological_substance 1609 1616	placebo
T90	GGPs 395 400	IL-13
N9	Reference T90 UMLS:C0214743	Interleukin-13
T107	GGPs 114 119	IL-13
N10	Reference T107 UMLS:C0214743	Interleukin-13
N6	Reference T81 UMLS:C1515021	Subgroup
N13	Reference T82 UMLS:C1515021	Subgroup
T2	Subject 1259 1264	group
N14	Reference T2 UMLS:C1257890	Population Group
T15	Subject 57 65	Subjects
N15	Reference T15 UMLS:C0681850	Study Subject
T22	Subject 278 286	subjects
N18	Reference T22 UMLS:C0681850	Study Subject
T32	Subject 425 433	subjects
N20	Reference T32 UMLS:C0681850	Study Subject
T46	Subject 470 478	Subjects
N21	Reference T46 UMLS:C0681850	Study Subject
T47	Subject 1341 1349	subjects
N24	Reference T47 UMLS:C0681850	Study Subject
T108	Subject 1477 1485	subjects
N25	Reference T108 UMLS:C0681850	Study Subject
R1	Subject_Disorder Arg1:T15 Arg2:T89	
R2	Subject_Disorder Arg1:T32 Arg2:T106	
N28	Reference E11 UMLS:C1519614	Genetic Translation Process
N5	Reference T37 UMLS:C0032042	Placebos
N7	Reference T43 UMLS:C0032042	Placebos
N8	Reference T63 UMLS:C0032042	Placebos
T27	Positive_regulation 265 274	increased
E3	Positive_regulation:T27 Theme:E11 disorder:T97
N30	Reference E3 UMLS:C1879547	Activation action
T38	Negative_regulation 1355 1362	decline
E4	Negative_regulation:T38 Theme:T110
N32	Reference E4 UMLS:C3463820	Inhibition
R4	part_of Arg1:T2 Arg2:T82	
T51	Biological_process 237 245	fibrosis
E7	Biological_process:T51 Theme:T65
T64	Biological_process 300 311	progressing
E8	Biological_process:T64 Theme:T97
N34	Reference E8 UMLS:C0242656	Disease Progression
T97	Disorder 312 319	disease
N35	Reference T97 UMLS:C0012634	Disease
R3	Subject_Disorder Arg1:T22 Arg2:T97	
T45	Measurement 632 653	percent predicted FVC
N37	Reference T45 UMLS:C2919678	Percentage of predicted forced vital capacity
T109	Measurement 1066 1087	percent predicted FVC
N38	Reference T109 UMLS:C2919678	Percentage of predicted forced vital capacity
T110	Measurement 1366 1387	percent predicted FVC
N39	Reference T110 UMLS:C2919678	Percentage of predicted forced vital capacity
T10	Artificial_process 479 487	received
E1	Artificial_process:T10 Instrument:T80 Theme:T46
T28	Biological_process 1544 1558	adverse events
E10	Biological_process:T28 Cause:E2
N41	Reference E10 UMLS:C0877248	Adverse event
T31	Biological_process 1653 1664	progression
E12	Biological_process:T31 Theme:T66
N43	Reference E12 UMLS:C0242656	Disease Progression
T21	Biological_process 1669 1681	exacerbation
E14	Biological_process:T21 Theme:T66
N42	Reference E14 UMLS:C4086268	Exacerbation
N33	Reference E7 UMLS:C0016059	Fibrosis
T34	Artificial_process 1469 1476	treated
E6	Artificial_process:T34 Instrument:T18 Theme:T108
T3	Correlation 222 226	role
E9	Correlation:T3 Theme:T107 Theme2:E7 Cue:T52
N4	Reference E9 UMLS:C0332281	Associated with
N50	Reference E1 UMLS:C1621583	Administer
E18	Artificial_process:T10 Instrument:T37 Theme:T46
N51	Reference E18 UMLS:C1621583	Administer
R6	member_of Arg1:T106 Arg2:T88	
T52	Speculation_cue 212 219	suggest
A1	Speculated E9
R7	member_of Arg1:T74 Arg2:T40	
T40	GGPs 390 420	anti-IL-13 monoclonal antibody
R8	member_of Arg1:T40 Arg2:T4	
N53	Reference T65 UMLS:C0819757	Structure of parenchyma of lung
N45	Reference E6 UMLS:C1621583	Administer
R9	member_of Arg1:T19 Arg2:T57	
R10	member_of Arg1:E12 Arg2:T57	
R11	member_of Arg1:E14 Arg2:T57	
R12	member_of Arg1:T5 Arg2:T57	
T57	Disorder 1544 1558	adverse events
N46	Reference T57 UMLS:C0877248	Adverse event
